Back to results
US 12,582,609 B2Granted
Cancer vaccines
AssigneeModernaTX, Inc.
InventorsNicholas Valiante, Tal Zaks, Eric Yi-Chun Huang
Life of this patent
Estimating the term…
Abstract
The disclosure relates to cancer ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Claims36
A personalized cancer vaccine for treating a cancer in a subject, comprising:
- a messenger ribonucleic acid (mRNA) having an open reading frame (ORF) encoding 5-100 peptide epitopes arranged in a head to tail formation, and
- a lipid nanoparticle, wherein the lipid nanoparticle comprises 5-25 mol % non-cationic lipid, 25-55 mol % sterol, 0.5-15 mol % polyethylene glycol (PEG)-modified lipid, and 20-60 mol % of a compound of Formula (I):
- or a salt thereof, wherein:
- R1 is selected from the group consisting of C5-30 alkyl, C5-20 alkenyl, and —R″M′R′;
- R2 and R3 are independently selected from the group consisting of C1-14 alkyl and C2-14 alkenyl;
- R4 is —(CH2)nQ, wherein Q is —OR, and n is selected from 1, 2, 3, 4, and 5;
- each R5 is H;
- each R6 is H;
- M and M′ are independently selected from —C(O)O— and —OC(O)—;
- R7 is H;
- R is H;
- R′ is selected from the group consisting of C1-18 alkyl and C2-18 alkenyl;
- R″ is selected from the group consisting of C3-14 alkyl and C3-14 alkenyl;
- and
- m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,
- wherein:
- (i) at least one of the peptide epitopes is a major histocompatibility complex (MHC) class I epitope and at least one of the peptide epitopes is an MHC class II epitope, and
- (ii) the mRNA comprises N1-methylpseudouridine.
15 more elements
A personalized cancer vaccine for treating a cancer in a subject, comprising:
- a messenger ribonucleic acid (mRNA) having an open reading frame (ORF) encoding 5-50 peptide epitopes arranged in a head to tail formation, and
- a lipid nanoparticle, wherein the lipid nanoparticle comprises 5-25 mol % non-cationic lipid, 25-55 mol % sterol, 0.5-15 mol % PEG-modified lipid, and 20-60 mol % compound of Formula (I):
- or a salt thereof, wherein:
- R1 is selected from the group consisting of C5-30 alkyl, C5-20 alkenyl, and —R″M′R′;
- R2 and R3 are independently selected from the group consisting of C1-14 alkyl and C2-14 alkenyl;
- R4 is —(CH2)nQ, wherein Q is —OR, and n is selected from 1, 2, 3, 4, and 5;
- each R5 is H;
- each R6 is H;
- M and M′ are independently selected from —C(O)O— and —OC(O)—;
- R7 is H;
- R is H;
- R′ is selected from the group consisting of C1-18 alkyl and C2-18 alkenyl;
- R″ is selected from the group consisting of C3-14 alkyl and C3-14 alkenyl;
- and
- m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13,
- wherein:
- (i) at least one of the peptide epitopes is an MHC class I epitope and at least one of the peptide epitopes is an MHC class II epitope, and
- (ii) the mRNA comprises N1-methylpseudouridine.
15 more elements
A personalized cancer vaccine for treating a cancer in a subject, comprising:
- a messenger ribonucleic acid (mRNA) having an open reading frame (ORF) encoding 5-50 cancer antigen peptide epitopes arranged in a head to tail formation, and
- a lipid nanoparticle, wherein the lipid nanoparticle comprises (i) 5-25 mol % non-cationic lipid selected from the group consisting of DSPC, POPC, DPPC, DOPE and SM, (ii) 25-55 mol % cholesterol, (iii) 0.5-15 mol % PEG-modified lipid selected from the group consisting of PEG-c-DOMG, PEG-DSG, PEG-DMG, PEG-DPG, and PEG-cDMA, and (iv) 20-60 mol % of Compound 25
- wherein:
- (i) at least one of the peptide epitopes is an MHC class I epitope and at least one of the peptide epitopes is an MHC class II epitope,
- (ii) at least two of the peptide epitopes are linked directly to one another without a linker,
- (iii) the mRNA further comprises a 5′ untranslated region (5′-UTR), a 3′ untranslated region (3′-UTR), a 5′ cap, and a poly-A tail, and
- (iv) the mRNA comprises N1-methylpseudouridine.
4 more elements
Dependencies are inferred from the claim text.